SAMSUNG-SEMICONDUCTOR
23.12.2021 10:02:09 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that it has developed the PM1743 SSD for enterprise servers, integrating the PCIe (Peripheral Component Interconnect Express) 5.0 interface with Samsung's advanced sixth-generation V-NAND.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005139/en/
"For over a decade, Samsung has been delivering SATA, SAS and PCIe-based SSDs that have been recognized for outstanding performance and reliability by leading enterprise server customers including corporations, governments and financial institutions," said Yong Ho Song, Executive Vice President and Head of the Memory Controller Development Team at Samsung Electronics. "The introduction of our PCIe 5.0 SSD, along with PCIe 6.0-based product developments that are underway, will further solidify our technological leadership in the enterprise server market."
"Intel has been working with Samsung to test Samsung's newest PCIe NVMe SSD, the PM1743. Together, we have jointly resolved complicated technical issues encountered with PCIe 5.0 during this initial evaluation period. The performance potential of Gen5 is truly impressive. In the near future, we strongly believe that PCIe Gen5 systems with high-speed NVMe SSDs will have the ability to transform applications such as AI/ML and high-performance databases," said Jim Pappas, Director, Technology Initiatives, Intel Corporation. "Looking ahead, we are confident that Intel and Samsung's continued commitment in industry leadership will provide these and other benefits to our mutual customers."
PCIe 5.0 offers a bandwidth of 32 gigatransfers per second (GT/s), doubling that of PCIe 4.0. Leveraging a proprietary controller designed to support the latest PCIe standard, the PM1743 will deliver outstanding read and write speeds to accommodate the rapidly increasing performance requirements of data centers.
Samsung’s PM1743 will feature a sequential read speed of up to 13,000 megabytes per second (MB/s) and a random read speed of 2,500K input/output operations per second (IOPS), offering 1.9x and 1.7x faster speeds over the previous PCIe 4.0-based products. Moreover, write speeds have been elevated significantly, with a sequential write speed of 6,600 MB/s and a random write speed of 250K IOPS, also delivering 1.7x and 1.9x faster speeds, respectively. These remarkable data transfer rates will allow enterprise server manufacturers deploying the PM1743 to enjoy a much higher level of performance.
In addition, the new SSD can provide improved power efficiency of up to 608 MB/s per watt, which represents about a 30% boost over the previous generation. This is expected to lower server and data center operating costs significantly, while also helping to reduce their carbon footprint.
Available in a wide variety of capacities from 1.92 terabytes (TB) to 15.36TB, the PM1743 will be offered in the conventional 2.5-inch form factor, as well as in a 3-inch EDSFF (E3.S) — an increasingly popular SSD form factor designed specifically for next-generation enterprise servers and data centers. Customers deploying 7.5mm EDSFF SSDs will be able to double the storage density in their systems, compared to when the 15mm 2.5-inch form factor is used. Coupled with excellent signal integrity and thermal efficiency, the EDSFF is ideal for most PCIe 5.0 enterprise solutions.
Furthermore, the PM1743 is expected to be the industry's first PCIe 5.0 SSD with dual-port support, guaranteeing server operational stability and high availability when a connection to one port fails.
Recently, the importance of data security has been growing stronger in the enterprise server market. To ensure that these needs are addressed, Samsung's PM1743 will implement advanced security features that were traditionally only available at the server level. By embedding a security processor and Root of Trust (RoT), the SSD will protect against security threats and data forgery to provide data confidentiality and integrity, while also enabling Secure Boot in server systems through attestation.
Samsung is now delivering samples of the PM1743 to global chipset and server manufacturers for joint system development. The company plans to begin mass producing the PM1743 in the first quarter of 2022, as it continues to foster a highly robust ecosystem for the new PCIe 5.0 standard.
The PM1743 has been designated a CES 2022 Innovation Awards Honoree in the category of Computer Hardware & Components.
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom